Midatech Pharma Plc P / E

Was ist das P / E von Midatech Pharma Plc?

P / E von Midatech Pharma Plc ist N/A

Was ist die Definition von P / E?

Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.

The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.

Was macht Midatech Pharma Plc?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Unternehmen mit p / e ähnlich Midatech Pharma Plc

UMT United Mobility Technology AG hat P / E von N/A
Alberton Acquisition hat P / E von N/A
Evergold hat P / E von N/A
Evergold Corp hat P / E von N/A
Teladoc Health hat P / E von N/A
TRU Precious Metals hat P / E von N/A
Midatech Pharma Plc hat P / E von N/A
Rite Aid hat P / E von N/A
OCL Iron and Steel hat P / E von N/A
Power Projects hat P / E von N/A
MAS Gold hat P / E von N/A
Freshlocal Solutions hat P / E von N/A
Woodbridge Ventures hat P / E von N/A